|
1
|
Kantarjian H, Ravandi F, O'Brien S, Cortes
J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce,
et al: Intensive chemotherapy does not benefit most older patients
(age 70 years or older) with acute myeloid leukemia. Blood.
116:4422–4429. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schiller GJ: When a gold standard is made
of tin. Blood. 116:4386–4387. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Santini V, Kantarjian HM and Issa JP:
Changes in DNA methylation in neoplasia: Pathophysiology and
therapeutic implications. Ann Intern Med. 134:573–586. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Baylin SB and Ohm JE: Epigenetic gene
silencing in cancer - a mechanism for early oncogenic pathway
addiction? Nat Rev Cancer. 6:107–116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jones PA and Takai D: The role of DNA
methylation in mammalian epigenetics. Science. 293:1068–1070. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Issa JP, Baylin SB and Herman JG: DNA
methylation changes in hematologic malignancies: Biologic and
clinical implications. Leukemia. 11:(Sul 1). S7–S11.
1997.PubMed/NCBI
|
|
7
|
Melki JR and Clark SJ: DNA methylation
changes in leukaemia. Semin Cancer Biol. 12:347–357. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Egger G, Liang G, Aparicio A and Jones PA:
Epigenetics in human disease and prospects for epigenetic therapy.
Nature. 429:457–463. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kantarjian HM, Thomas XG, Dmoszynska A,
Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R,
Cermak J, et al: Multicenter, randomized, open-label, phase III
trial of decitabine versus patient choice, with physician advice,
of either supportive care or low-dose cytarabine for the treatment
of older patients with newly diagnosed acute myeloid leukemia. J
Clin Oncol. 30:2670–2677. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Issa JP, Garcia-Manero G, Giles FJ,
Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS,
Cortes J, et al: Phase 1 study of low-dose prolonged exposure
schedules of the hypomethylating agent 5-aza-2′-deoxycytidine
(decitabine) in hematopoietic malignancies. Blood. 103:1635–1640.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang AS, Doshi KD, Choi SW, Mason JB,
Mannari RK, Gharybian V, Luna R, Rashid A, Shen L, Estecio MR, et
al: DNA methylation changes after 5-aza-2′-deoxycytidine therapy in
patients with leukemia. Cancer Res. 66:5495–5503. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li K, Hu C, Mei C, Ren Z, Vera JC, Zhuang
Z, Jin J and Tong H: Sequential combination of decitabine and
idarubicin synergistically enhances anti-leukemia effect followed
by demethylating Wnt pathway inhibitor promoters and downregulating
Wnt pathway nuclear target. J Transl Med. 12:1672014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gore SD, Baylin S, Sugar E, Carraway H,
Miller CB, Carducci M, Grever M, Galm O, Dauses T, Karp JE, et al:
Combined DNA methyltransferase and histone deacetylase inhibition
in the treatment of myeloid neoplasms. Cancer Res. 66:6361–6369.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Blum W, Klisovic RB, Hackanson B, Liu Z,
Liu S, Devine H, Vukosavljevic T, Huynh L, Lozanski G, Kefauver C,
et al: Phase I study of decitabine alone or in combination with
valproic acid in acute myeloid leukemia. J Clin Oncol.
25:3884–3891. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vardiman JW: The World Health Organization
(WHO) classification of tumors of the hematopoietic and lymphoid
tissues: an overview with emphasis on the myeloid neoplasms.
Chem-Biol Interact. 184:16–20. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheson BD, Bennett JM, Kopecky KJ, Büchner
T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister
TA, et al: International Working Group for Diagnosis,
Standardization of Response Criteria, Treatment Outcomes, and
Reporting Standards for Therapeutic Trials in Acute Myeloid
Leukemia: Revised recommendations of the International Working
Group for Diagnosis, Standardization of Response Criteria,
Treatment Outcomes and Reporting Standards for Therapeutic Trials
in Acute Myeloid Leukemia. J Clin Oncol. 21:4642–4649. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Postma TJ and Heimans JJ: Grading
chemotherapy-induced peripheral neuropathy. Ann Oncol. 11:509–513.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lübbert M, Suciu S, Baila L, Rüter BH,
Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U,
Salih HR, et al: Low-dose decitabine versus best supportive care in
elderly patients with intermediate- or high-risk myelodysplastic
syndrome (MDS) ineligible for intensive chemotherapy: Final results
of the randomized phase III study of the European Organisation for
Research and Treatment of Cancer Leukemia Group and the German MDS
Study Group. J Clin Oncol. 29:1987–1996. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Leonard SM, Perry T, Woodman CB and Kearns
P: Sequential treatment with cytarabine and decitabine has an
increased anti-leukemia effect compared to cytarabine alone in
xenograft models of childhood acute myeloid leukemia. PLoS One.
9:e874752014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Peng CY, Jiang J, Zheng HT and Liu XS:
Growth-inhibiting effects of arsenic trioxide plus epigenetic
therapeutic agents on leukemia cell lines. Leuk Lymphoma.
51:297–303. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Qin T, Youssef EM, Jelinek J, Chen R, Yang
AS, Garcia-Manero G and Issa JP: Effect of cytarabine and
decitabine in combination in human leukemic cell lines. Clin Cancer
Res. 13:4225–4232. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang YP, Wu WZ and Cui GX: Comparison of
clinical efficacy between decitabine combined with CAG regimen and
CAG regimen alone in patients with intermediate to high-risk
myelodysplastic syndromes. J Exp Hematol. 22:1341–1344. 2014.(In
Chinese). PubMed/NCBI
|
|
23
|
Jing Y, Zhu CY, Zhang Q, et al: Clinical
efficacy of decitabine combined with modified CAG regimen for
relapsed-refractory acute myeloid leukemia with
AML1-ETO+. J Exp Hematol. 22:1245–1250. 2014.(In
Chinese). PubMed/NCBI
|
|
24
|
Benton CB, Thomas DA, Yang H, Ravandi F,
Rytting M, O'Brien S, Franklin AR, Borthakur G, Dara S, Kwari M, et
al: Safety and clinical activity of 5-aza-2′-deoxycytidine
(decitabine) with or without Hyper-CVAD in relapsed/refractory
acute lymphocytic leukaemia. Br J Haematol. 167:356–365. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bhatnagar B, Duong VH, Gourdin TS, Tidwell
ML, Chen C, Ning Y, Emadi A, Sausville EA and Baer MR: Ten-day
decitabine as initial therapy for newly diagnosed patients with
acute myeloid leukemia unfit for intensive chemotherapy. Leuk
Lymphoma. 55:1533–1537. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mutze K, Langer R, Schumacher F, Becker K,
Ott K, Novotny A, Hapfelmeier A, Höfler H and Keller G: DNA
methyltransferase 1 as a predictive biomarker and potential
therapeutic target for chemotherapy in gastric cancer. Eur J
Cancer. 47:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Robert MF, Morin S, Beaulieu N, Gauthier
F, Chute IC, Barsalou A and MacLeod AR: DNMT1 is required to
maintain CpG methylation and aberrant gene silencing in human
cancer cells. Nat Genet. 33:61–65. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Daskalakis M, Blagitko-Dorfs N and
Hackanson B: Decitabine. Recent Results Cancer Res. 184:131–157.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Oki Y, Aoki E and Issa JP: Decitabine -
bedside to bench. Crit Rev Oncol Hematol. 61:140–152. 2007.
View Article : Google Scholar : PubMed/NCBI
|
